Company intelligence / Profile preview

Laboratoires CTRS

Boulogne-Billancourt, Île-de-France, Francectrs.fr ↗

Ownership: Private
Employees: ~49
Development stage: Other

Overview

Laboratoires CTRS specializes in the development and commercialization of therapies for rare and ultra‐rare diseases. Its lead product, Orphacol® (cholic acid), treats patients with specific genetic defects affecting bile acid synthesis. The company has established international partnerships to ensure access to its products and has completed clinical studies on pediatric formulations.

Therapeutic areas: Metabolic DisordersOncologyRare Diseases
Modalities: small molecules (notably cholic acid/Orphacol®)possible additional modalities in rare and ultra-rare diseases, but not explicitly detailed in sources
Industry: Biotech

Partnerships

Abacus Medicine Pharma Services – distribution partnership for Orphacol® in Spain and potentially other markets.

Beyond the preview

Go deeper on Laboratoires CTRS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratoires CTRS.